에 대한 최신 뉴스 Alzamend Neuro (NASDAQ:ALZN) 주식

ALZAMEND NEURO INC

Alzamend Neuro

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Stocks Photo by WHYFRAME on Shutterstock

Equities

News

Markets

ALZN

NVDA

PANW

TSLA

월요일 주요 미국 지수들은 상승세로 마감했다. 다우존스 산업평균지수는 0.6% 상승한 40,896.53에 마감했고, S&amp;P 500 지수는 거의 1% 상승한 5,608.25에 마감했다. 나스닥은 가장 큰 상승세를 보이며 17,876.77로 거의 1.4% 상승하며 하루를 마감했다.

월요일 주목받은 주식 5종목: 엔비디아, AMD, 알자멘드 뉴로, 팔로알토 네트웍스, 테슬라

Alzamend Neuro Inc

WisdomTree, an international asset manager, has grown its portfolio with the introduction of two new municipal bond ETFs: the WisdomTree Core Laddered Municipal Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTMU#NASDAQ">WTMU</a>) and the WisdomTree High Income Laddered Municipal Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTMY#NASDAQ">WTMY</a>). These <a href="https://www.benzinga.com/etfs">funds are designed to offer</a> investors tax-efficient income and diversification advantages.​
These funds are <a href="https://www.businesswire.com/news/home/20250403281335/en/WisdomTree-Launches-Core-Laddered-and-High-Income-Laddered-Municipal-ETFs">currently </a>trading at expense ratios of 0.25% and 0.35%, respectively.
Also Read: <a href="https://www.benzinga.com/etfs/new-etfs/25/04/44633519/vaneck-moves-closer-to-us-binance-coin-etf-but-will-the-sec-play-ball">VanEck Moves Closer To US Binance Coin ETF — But Will The SEC Play Ball?</a>
In today&#8217;s changing fixed-income environment, investors are increasingly looking for stability and income. Municipal bonds provide high credit quality, lower default rates compared to corporate bonds, and strength in rising-rate environments, which makes them an attractive option.
WTMU has a laddered maturity strategy of investing in municipal debt securities and can invest up to 30% of its assets in municipal securities subject to the federal alternative minimum tax. The fund seeks an average duration of between four and eight years, targeting securities that should mature or become callable within 15 years.
The ETF seeks current income that is tax-exempt at the federal level.
WTMY has a similar laddered strategy but aims to maximize income and yield by delivering a high current income that is free from federal income taxes. It has a targeted mix of high-yield municipal securities and investment-grade municipals. The fund aims for an average duration of five to ten years, focusing on securities likely to mature or be callable within 15 years.
The rollouts follow the increasing popularity of municipal bond funds. <a href="https://www.benzinga.com/etfs/specialty-etfs/25/03/44384618/new-ishares-muni-bond-etf-lmub-hits-nyse-as-demand-surges">BlackRock rolled out</a> the iShares Long-Term National Muni Bond ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMUB#NYSE">LMUB</a>) in March with an expense ratio of 0.09% to provide investors with investment-grade U.S. municipal bonds with maturities of 12 years or more. 
Municipal bonds are becoming increasingly popular as a result of their potential tax benefits and relatively strong credit quality versus corporate bonds. They can also offer diversification benefits and potentially have defensive properties in a rising interest rate environment. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44633773/textbook-lesson-this-leveraged-etf-plunged-73-since-inception-a-warning-for-crypto-investors">Textbook Lesson: This Leveraged ETF Plunged 73% Since Inception – A Warning For Crypto Investors?</a></li>
</ul>
Photo: Shutterstock

New ETFs

ETFs

BYLD

LMUB

WTMU

WTMY

Looking For Shelter? WisdomTree's Latest ETFs Target Stability In Shaky Bond Market

Guidance

Exxon Mobil Discloses Earnings Considerations That Will Impact Q1 2025 Results Relative To 4Q 2024 Results

Under the franchise structure, the hotel will continue to be the Sofitel Chicago Magnificent Mile, but will be managed by Remington Hospitality under the existing terms of its Master Hotel Management Agreement with Braemar.&nbsp;

Braemar Hotels Plans To Transition The 415-room Sofitel Chicago Magnificent Mile To Franchise Structure

RIOT

Riot Platforms Mined 533 Bitcoin In March 2025, Up 25% YoY And 13% From February

Sangamo Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) shares are surging in Thursday&#8217;s after-hours session after the company announced a new agreement with <a href="https://www.benzinga.com/pressreleases/25/04/b44635260/sangamo-therapeutics-announces-capsid-license-agreement-with-lilly-to-deliver-genomic-medicines-fo">pharmaceutical giant Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</a>.
What Happened: Sangamo Therapeutics entered into a license agreement with Eli Lilly, granting the company a worldwide exclusive license to leverage the company&#8217;s novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB.
Sangamo noted that STAC-BBB has demonstrated potent blood-brain barrier penetration and neuronal transduction in nonhuman primates.
The genomic medicine company said the license allows Eli Lilly to utilize the STAC-BBB capsid for one initial target. Eli Lilly has the right to add up to four additional targets, but will be required to pay additional license fees.
Sangamo will receive an upfront payment of $18 million and is eligible to earn up to $1.4 billion in additional license fees and milestone payments.
&#8220;We believe STAC-BBB, our industry-leading intravenously delivered AAV capsid, has the potential to play an important role in the treatment landscape by addressing longstanding challenges associated with delivering therapies to the central nervous system,&#8221; said Sandy Macrae, CEO of Sangamo.
&#8220;We are pleased to be sharing STAC-BBB with Lilly to advance potential treatments for neurological diseases with significant unmet medical needs. This marks the third agreement with a pharmaceutical company since we announced the discovery of STAC-BBB in March 2024 and demonstrates the continued industry interest in our capsid delivery technology.&#8221;
Sangamo will be responsible for completing a technology transfer related to the STAC-BBB capsid. Lilly will be responsible for all research, preclinical and clinical development, regulatory interactions, manufacturing and global commercialization of any resulting gene therapy products.
SGMO Price Action: <a href="http://benzinga.com/quote/sgmo">Sangamo shares</a> were up 26.13% after hours, trading at 78 cents at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Courtesy of Sangamo Therapeutics.

Biotech

Health Care

After-Hours Center

Movers

SGMO

Sangamo Therapeutics Stock Surges After The Bell: What's Going On?

JPMorgan Research has upgraded its outlook for <a href="https://www.benzinga.com/topic/mining">European mining equities</a>, shifting more positive in February and then upgrading the outlook to Overweight in March. The research team cited a pattern of the sector outperforming through economic turbulences, believing a historical pattern could repeat.
Yet analysts acknowledge that the prediction hinges on the timing of China&#8217;s policy response—an important factor since its economy accounts for over 50% of global demand for most industrial metals. JPMorgan forecasts the reaction will focus on fiscal and monetary easing rather than property sector stimulus.
Owing to U.S. tariff policies, the bank now sees a <a href="https://www.benzinga.com/25/04/44608617/jp-morgan-hikes-us-recession-odds-to-40-tariffs-create-a-dilemma-for-the-fed">40% chance of a domestic recession</a> this year, and China's GDP slowdown to 3% in Q2, down from 6.6% in Q1.&nbsp; With reciprocal tariffs, the effective rate on Chinese goods has now jumped to 54%, close to the bank's base case scenario of 60%.
Analysts have pointed out that European miners face limited direct exposure, although Rio Tinto's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIO#NYSE">RIO</a>) Canadian aluminum operations are affected. Still, the sector's upside depends on copper price stability. A sustained copper rally could present a multi-year entry point, but downside risks include demand destruction from a global recession and a weaker Chinese yuan, which historically correlates with lower metal prices.
The bank highlights Antofagasta (OTCPK: ANFGF) as its Overweight pick, citing its 15–30% volume growth through 2027–28 and attractive valuation as its Centinela expansion ramps up. It also favors Lundin Mining (OTCPK: LUNMF), arguing it trades at a discount, close to 5X EV/EBITDA, compared to peers, which trade at 9-10X. Furthermore, it faces reduced governance risks <a href="https://www.benzinga.com/markets/equities/24/07/40031488/bhp-to-unlock-south-american-copper-riches-partners-with-lundin-for-filo-acquisition">following Vicuña transactions</a>. Regarding the sector leaders, they're Overweight Rio Tinto (citing inexpensive valuation and high copper upside) and Neutral on Anglo American and BHP.
On the downside, the bank is Underweight Boliden, pointing to lower treatment and refining charges, exposure to zinc, and integration challenges after acquiring Lundin's two European mines for <a href="https://www.benzinga.com/24/12/42385859/lundin-exits-europe-for-15-billion-turns-focus-to-south-america">$1.5 billion last year</a>.
The bank remains bullish on EMEA gold miners, projecting a 30% rise in gold prices to ~$4,000/oz amid geopolitical and macroeconomic uncertainty. The top pick is Fresnillo (OTCPK: FNLPF), which it sees benefiting from potential Mexican peso weakness.
European steel equities are less favored due to direct tariff exposure, particularly in auto-dependent firms like ThyssenKrupp and Voestalpine (~30–40% revenue exposure). Furthermore, the bank sees ArcelorMittal facing $400 million in annual EBITDA headwinds from tariffs, but clarifies that SSAB stands out with 45% of EBITDA from the U.S. infrastructure and defense sectors, insulating it from broader tariff risks.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44623954/metals-avoid-trumps-reciprocal-tariffs-white-house-expects-domestic-industry-tailwinds">Metals Avoid Trump&#8217;s Reciprocal Tariffs, White House Expects Domestic Industry Tailwinds</a></li>
</ul>
Photo: Shutterstock

Upgrades

Commodities

Analyst Ratings

ANFGF

FNLPF

LUNMF

JPMorgan Turns Bullish On European Miners, Sees Copper Rally As Key Catalyst

When volatility spikes, as it did yesterday following the reveal of the President&#8217;s new import taxes, &#8220;tape bombs&#8221; appear everywhere. As a trader and long term investor, when that happens I zoom out in the charts.
There are times in the markets where risk becomes more outsized, and this is one of those times. Size down, slow down becomes my mantra. Capital preservation becomes key.
There are option trades that let you do just that – preserve capital, wait out the churn, while still making some options income.
Here&#8217;s how to ignore the market chaos and position yourself for profits.
We&#8217;re going to target ONEOK Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKE#NYSE">OKE</a>) today, with a long call butterfly. This kind of option trade is the combination of a long call spread, and a short call spread that share the same short strike and the same expiration date.
We&#8217;re positioning the option trade well into the future (using a bullish position that gives us time to wait out the sideways churn ahead), which is why it&#8217;s termed a &#8220;leap&#8221; trade.
OKE&#8217;s relative resistance zone sits right around $120, but trading could be choppy for many months with market uncertainty. Set an alert for prices near this middle strike so that you are very aware of the motion into the middle strike as this is where the maximum profit will engage into expiration. You will also notice that price action is less sensitive to fluctuation the further we are from expiration. OKE&#8217;s support sits near $88.
The beauty of a leap butterfly is that time decay becomes largely irrelevant, so we can wait out the noisy bits in the market as we recover. Here&#8217;s the trade, positioned for upside:
<ul>
<li>Buy to open 1 OKE 18 Jun 2025 105 calls </li>
<li>Sell to open 2 OKE 18 Jun 2025 120 calls </li>
<li>Buy to open 1 OKE 18 Jun 2025 135 calls </li>
</ul>
The long call butterfly holds a current debit of $2.38 at this writing and that represents the total risk incurred in the trade. The breakeven price of the stock at expiration on this trade is $107.38 + commissions.
The total highest potential profit is $15 (the distance between 105 and 120) less the cost of the debit incurred by buying the call butterfly: $15 minus $2.38 = $12.62 less commissions.&nbsp;
It is extremely rare to collect all this premium in this kind of butterfly. Instead, I like to consider 40%-90% profit of the longer-term investment. Also keep in mind that these leaps have favorable tax implications.
This strategy provides for several ways to exit, but these are the two main ones:
<ol>
<li>To sell the call butterfly when the profit goal moves into your target parameters-particularly once the middle strike is tested near the expiration time. I often look for 40%-90% return for these types of call butterflies with strikes deep in the money. </li>
<li>To sell the call butterfly when your loss threshold is breached. Customarily, this is 50% for me. </li>
</ol>
Remember to size down as markets fluctuate – it is more important to focus more on what we can lose than on what we can make.
<a href="https://www.benzinga.com/premium/ideas/7-day-free-trial-matt-maley-inner-circle/?el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}&amp;utm_adType=SponsorAd&amp;utm_ad=RD0404&amp;utm_campaign=7daytrial/">Make This Unpredictable Market Work for Your Income</a>
Matt&#8217;s 35-year Wall Street experience helps members identify profit zones others miss—in any direction. <a href="https://www.benzinga.com/premium/ideas/7-day-free-trial-matt-maley-inner-circle/?el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}&amp;utm_adType=SponsorAd&amp;utm_ad=RD0404&amp;utm_campaign=7daytrial/">Free 7-day access. Make Market Chaos Your Investment Advantage</a>
Image via Shutterstock

Opinion

Trading Ideas

How To Get Safe Income During This Crash

Highlights Plan to Improve Performance, Strengthen Accountability and Increase Shareholder Value
Identifies Slate of Four Highly Qualified Independent Director Candidates with Decades of Experience in Refining, Midstream Operations and Corporate Governance&nbsp;
More Information at <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4398557-1&amp;h=3336979746&amp;u=http%3A%2F%2Fwww.streamline66.com%2F&amp;a=Streamline66.com">Streamline66.com</a>
WEST PALM BEACH, Fla., April 3, 2025 /PRNewswire/ -- Elliott Investment Management L.P. ("Elliott"), which manages funds that together have an investment of more than $2.5 billion in Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) (the "Company" or "Phillips"), today sent a letter to the Company's shareholders highlighting why change is urgently needed on the Phillips Board of Directors (the "Board"). In the letter, Elliott made the case that Phillips investors' patience has been punished, and a new lineup on the Board is necessary to reverse the Company's long-term underperformance and improve its poor corporate governance practices. Elliott also filed definitive proxy materials in connection with Phillips' Annual Meeting of Stockholders (the "Annual Meeting"), which is currently scheduled for May 21, 2025.
<a href="https://mma.prnewswire.com/media/2657884/Elliott_Letter_to_Phillips_66_Shareholders.pdf?p=original"><img src="https://mma.prnewswire.com/media/2657884/Elliott_Letter_to_Phillips_66_Shareholders.pdf?p=pdfthumbnail" alt="Letter to Phillips 66 Shareholders" /></a>
In its materials, Elliott detailed the degree to which Phillips' operating performance has consistently trailed its industry peers. Notably, over the past decade, Phillips shares have underperformed Valero Energy and Marathon Petroleum, by -138% and -188%, respectively.
In addition, Elliott discussed why its three-part "Streamline 66" plan – which Elliott believes has the potential to increase Phillips' stock price to more than $200 per share – would be the best path forward. The plan includes a simplification of Phillips' portfolio, a thorough review of its refinery operations and enhanced oversight of management at the Board level.
Elliott also disclosed its four highly qualified director nominees, who would add urgently needed experience and valuable new perspectives to the Board:
<ul>
<li>Sigmund Cornelius&nbsp;served as CFO at the predecessor company of Phillips, ConocoPhillips, where he oversaw a substantial divestiture and simplification program that led to a material increase in shareholder value. He later served as President of Freeport LNG Development, as well as a director at Andeavor and Western Refining. &nbsp;</li>
<li>Michael&nbsp;Heim&nbsp;has a long record of leadership in the industry as a founder of Targa Resources, one of the most successful Permian-focused midstream operators, and as a member of multiple boards and a respected consultant. &nbsp;</li>
<li>Brian&nbsp;Coffman&nbsp;is a seasoned operator who spent much of his career running Phillips' current refining assets while they were part of ConocoPhillips. After three decades at ConocoPhillips, he became the executive in charge of refining for Andeavor, leading the operations of ten refineries throughout the United States, as well as the President and CEO of Motiva, one of North America's largest refiners. &nbsp;</li>
<li>Stacy&nbsp;Nieuwoudt&nbsp;would bring an investor's eye to Phillips' challenges, having spent her career as a senior energy and industrials analyst at Citadel. She has also served on the boards of multiple publicly traded energy companies.</li>
</ul>

Elliott Investments Sends Letter To Shareholders And Mails Definitive Proxy Materials Outlining Why Board Change Is Needed At Phillips 66

RETO

ReTo Regains Compliance With Nasdaq's Minimum Bid Price Requirement

ALUR

Allurion Postpones Special Meeting Of Stockholders From April 4, 2025 To April 10, 2025

Former White House communications director Anthony Scaramucci probably <a href="https://www.benzinga.com/news/25/04/44608167/liberation-day-is-liquidation-day-says-anthony-scaramucci-heres-how-it-could-hit-your-wallet">said it the best</a>: "Liberation Day is Liquidation Day." Describing the sweeping wave of new tariffs announced on Wednesday by President Donald Trump, the reciprocal levies are designed to help American workers and revive U.S. manufacturing. 
Unfortunately, the move is creating a ripple effect on pricing implications, badly hurting technology specialists, including integrated circuits manufacturer Tower Semiconductor Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSEM#NASDAQ">TSEM</a>).
At first glance, Tower doesn't particularly stand out as a tariff-vulnerable candidate. Although based in Israel, the U.S. has a close relationship with the country. According to the New York Times, the two allies have had a free-trade <a href="https://www.nytimes.com/2025/04/02/us/politics/israel-tariffs-us-imports-trump.html#:~:text=Israel%20and%20the%20United%20States%2C%20two%20close%20allies%2C%20have%20had,American%20products%20from%20Israeli%20tariffs.">agreement</a> since 1985. However, the core issue centers on the <a href="https://www.benzinga.com/25/04/44613907/tariff-shock-incoming-as-trump-prepares-sweeping-trade-duties-what-traders-need-to-know">stability of the global supply chain</a>.
Modern businesses — especially within the advanced semiconductor industry — require specialized parts and materials that are secured months in advance. Further, the research and development of advanced components can take years, requiring significant investments and partnerships across multiple entities. Plus, with so much of the tech ecosystem dependent on Asia, Trump's tariffs darken forward visibility.
More broadly, TSEM stock is also struggling from competitive threats. Earlier this year, China's DeepSeek rattled the tech sector, delivering an artificial intelligence model that could <a href="https://www.benzinga.com/25/01/43259545/deepseeks-r1-is-impressive-but-openai-ceo-sam-altman-says-they-will-crush-it-with-much-better-models-looking-forward-to-bringing-you-all-agi-and-beyond">compete with western counterparts at a much lower cost</a>. Such efficiencies potentially impinge upon Tower's business due to less demand for high-performance chips or even a potential realignment of supply chains.
<h2 class="wp-block-heading">TSEM Stock Enjoys Credibility as a Bounce-Back Prospect</h2>
Although the environment for TSEM stock appears incredibly dour, students of market history will look on the red ink with anticipation, not dread. More often than not, the ominous clouds have represented an opportunity to acquire shares.
First, Benchmark analyst Cody Acree stated that TSEM stock was one of the names to pick up following January's DeepSeek-inspired rout. The expert noted the company's <a href="https://www.benzinga.com/trading-ideas/movers/25/01/43285482/tower-semiconductor-analyst-sees-attractive-buying-opportunity-following-deepseek-selloff">resilience and growth potential</a>, specifically highlighting its leadership in radio frequency (RF) infrastructure technologies. This innovation is especially critical to applications involving the Industrial Internet of Things (IIoT), Tower's key specialty. Second, while TSEM stock printed the dreaded death cross earlier this week, this technical pattern — where the 50-day moving average slips below the 200 DMA — has historically served as a contrarian indicator. Between August 2015 and October 2022, there have been seven death crosses, with five of the incidences (or 71.4%) resolving to the upside one month later.
To be sure, the sample size is very small, so the implication needs to be taken with a grain of salt. Nevertheless, it's remarkable that even one year removed from the death cross flashing, the contrarian success ratio of 71.4% still stands.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03151257/TSEM-stock-probabibility-gambit-1024x576.jpg" alt="" class="wp-image-856351" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03151257/TSEM-stock-probabibility-gambit-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03151257/TSEM-stock-probabibility-gambit-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03151257/TSEM-stock-probabibility-gambit-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03151257/TSEM-stock-probabibility-gambit.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure>
Third, TSEM stock is currently down more than 11% over the trailing five sessions. Such extreme volatility is rare. Looking back over the past six years, there have only been four weeks where TSEM lost double-digit percentage points. By the fourth week following such an intense downside, the security has swung up three times, suggesting that investors recognize the deep value play.
<h2 class="wp-block-heading">Rolling the Dice on Tower Semiconductor</h2>
For those that want to go for the immediate gratification route, the nearest expiration date for TSEM stock options is April 17. Here, the 30/35 bull call spread would arguably be the most aggressive trade that has a realistic chance of being successful.
The above transaction involves buying the $30 call (at a time-of-writing ask) of $330 and simultaneously selling the $35 call (at a bid of $45), resulting in a net cash outlay of $285. Should TSEM stock hit or exceed the short strike price at expiration, the maximum reward is the difference between the strike prices (multiplied by 100 shares) minus the cash outlay or $215. This translates to a payout of 75.44%.
For speculators who want to play the death cross, they may consider buying the 35/37 bull spread for the options chain expiring May 16. This options chain provides more time for the market to bake in the negativity before hopefully rising. In the ensuing bounce back, strong double-digit-percentage moves are not unusual; hence, the ambitious but realistic $37 target.
Those who want to roll the dice on the above trade will need to spend $65. On the plus side, if TSEM stock cooperates, the maximum reward is $135 or a payout of nearly 208%.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44635144/fridays-jobs-report-could-be-make-or-break-moment-after-trumps-tariff-shock">Friday&#8217;s Jobs Report Could Be Make-Or-Break Moment After Trump&#8217;s Tariff Shock</a></li>
</ul>
Photo: Shutterstock

Options

Tech

TSEM

Options Corner: 'Liberation Day' Panic Flashes A Contrarian Signal For Tower Semiconductor

<a href="https://www.benzinga.com/news/25/03/44375147/smart-puppies-are-smarter-than-ai-mark-cubans-surprising-take-on-the-future-of-artificial-intelligence">Artificial intelligence</a> can churn out scripts, generate music, and even create entire films in minutes. But does that mean human creatives are on the way out? Not according to billionaire investor <a href="https://www.benzinga.com/startups/25/01/43084861/mark-cubans-29-million-shark-tank-portfolio-from-200k-in-dude-wipes-to-200m-for-beatbox-beverages-im-killing-it">Mark Cuban</a>.
Cuban, known for his bold takes on business and technology, recently addressed AI's role in entertainment on the <a href="https://www.youtube.com/watch?v=lUwmA0lOWwM">"Your Mom's House" </a>podcast.&nbsp;
"AI can propose a million things in a second, but then somebody&#8217;s got to go through and decide what they&#8217;re going to put their money into,&#8221; he said. His take? AI is just a tool, not the mastermind behind Hollywood's next big hit.
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>
<h2 class="wp-block-heading">The AI Takeover Fear Is Real</h2>
Not everyone shares Cuban's confidence. The 2023 Hollywood writers' and actors' strikes were fueled by fears that AI could replace screenwriters and performers altogether.&nbsp;
Over 11,000 writers, represented by the Writers Guild of America, walked off the job to demand stronger protections against AI-generated scripts. SAG-AFTRA joined the fight, pushing for safeguards as AI technology advanced at a breakneck pace.
The fear isn't unfounded. A study by the <a href="https://www.brookings.edu/articles/generative-ai-the-american-worker-and-the-future-of-work/?utm_source=chatgpt.com">Brookings Institution</a> found that AI is already disrupting industries that rely on dynamic information processing, including creative fields like writing and software development.&nbsp;
According to the <a href="https://www.ft.com/content/0ac1fe79-4c2a-4030-8046-061293ba1127?accessToken=zwAGEWkI51bokc8Kwf55TCpAMNOARgYSk7oRJw.MEQCIG5-PQaa6iGLaikfBFtPehc-hzozRviMYt85T9M7DDvLAiBgfIMjMZBGPCW26esEtNmB134EiMbOs6AoNHkJ5hEGRQ&amp;sharetype=gift&amp;token=de99c9c8-c493-4cf6-842f-2b54a83b2bbf&amp;utm_source=chatgpt.com">Financial Times</a>, AI-driven content creation tools have already replaced some entry-level creative roles.
Hollywood has seen attempts to use technology to predict blockbusters before—usually with mixed results. Studios have long relied on data analytics to determine which scripts and actors will generate the biggest returns.&nbsp;
Trending: BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a>
But Cuban isn't convinced AI will crack the code. &#8220;I&#8217;ve seen companies that use analytics to determine what a studio or label should release, fail time after time,&#8221; he said<a href="https://africa.businessinsider.com/entertainment/mark-cuban-says-ai-cant-completely-automate-the-creative-process/1f43wt7">.</a> &#8220;That&#8217;s the same as using AI to replace everyone. It may be a novelty. But it won&#8217;t work.&#8221;
This isn't the first time a new technology has threatened to upend the entertainment world. In the early 2000s, digital music-sharing platforms like Napster disrupted the music industry, sending record labels into a panic.&nbsp;
But rather than kill the industry, it paved the way for streaming services like Spotify (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>), which now dominate the market.
The invention of photography in the 19th century sparked fears that traditional painting would become obsolete. Instead, artists adapted, leading to new movements like Impressionism and modern art.
See Also: Have $200K saved?<a href="https://www.benzinga.com/money/have-200k-saved-heres-how-to-turn-it-into-lasting-wealth"> Here's how to turn it into lasting wealth</a>
Cuban believes the same evolution will happen with AI. &#8220;It's part of the natural progression from drawing to CGI and now text to video, with new tools coming to take it even further." Cuban isn't against AI—far from it.&nbsp;
He sees it as a way for top creatives to refine their work and make their process more efficient. &#8220;Veteran creatives who are able to harness the power of AI to improve their own output will continue to see major dividends,&#8221; he said.&nbsp;
AI, he argues, will help top-tier talent become even better by accelerating storyboarding, testing, and production.
Still, Cuban is clear: AI lacks the gut instinct that makes creative work resonate with audiences. "There is a reason why some people have hit after hit&#8230; They have a feel for what the audience wants at that point in time," he said.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>

Personal Finance

SPOT

AI Won't Steal Hollywood's Magic, Says Mark Cuban – 'The Best Will Get Even Better, But AI Can't Replace That Feel'

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CNGGF">Cann Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNGGF#OTC">CNGGF</a>) shares closed up 217.50% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed up 47.06% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed up 29.82% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed up 8.38% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/CARA">Cara Therapeutics</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares closed up 7.45% at $4.95</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 6.52% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/MRMD">MariMed</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed up 6.43% at $0.10</li>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed up 5.56% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed up 4.33% at $0.19</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/GBHPF">Global Hemp Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GBHPF#OTC">GBHPF</a>) shares closed down 71.43% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed down 24.00% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed down 17.30% at $0.15</li>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed down 16.93% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">FLUENT</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed down 10.00% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/GRWG">GrowGeneration</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) shares closed down 9.50% at $0.98</li>
<li><a href="https://www.benzinga.com/quote/SMG">Scotts Miracle Gro</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMG#NYSE">SMG</a>) shares closed down 8.28% at $53.16</li>
<li><a href="https://www.benzinga.com/quote/BLOZF">Cannabix Technologies</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLOZF#OTC">BLOZF</a>) shares closed down 7.38% at $0.42</li>
<li><a href="https://www.benzinga.com/quote/ESE">ESCO Technologies</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESE#NYSE">ESE</a>) shares closed down 7.28% at $148.82</li>
<li><a href="https://www.benzinga.com/quote/IIPR">Innovative Ind Props</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIPR#NYSE">IIPR</a>) shares closed down 7.20% at $52.42</li>
<li><a href="https://www.benzinga.com/quote/CRLBF">Cresco Labs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) shares closed down 6.77% at $0.62</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Glb Inv</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed down 6.72% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed down 6.00% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Gwth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed down 5.76% at $0.95</li>
<li><a href="https://www.benzinga.com/quote/VFF">Village Farms Intl</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) shares closed down 5.10% at $0.57</li>
<li><a href="https://www.benzinga.com/quote/OGI">Organigram Global</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) shares closed down 4.60% at $0.98</li>
<li><a href="https://www.benzinga.com/quote/TCNNF">Trulieve Cannabis</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) shares closed down 4.57% at $3.55</li>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed down 4.56% at $0.27</li>
<li><a href="https://www.benzinga.com/quote/SOL">Emeren Group</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) shares closed down 4.29% at $1.57</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed down 4.29% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed down 4.28% at $0.62</li>
<li><a href="https://www.benzinga.com/quote/CWBHF">Charlottes Web Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTC">CWBHF</a>) shares closed down 3.78% at $0.09</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed down 3.71% at $1.63</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed down 3.49% at $0.43</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

BLOZF

CARA

CBDY

CLSH

CNGGF

CNTMF

CRLBF

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

CWBHF

CXXIF

FFNTF

GBHPF

GNLN

GRWG

IIPR

ITHUF

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

LMLLF

MRMD

NWVCF

OILFF

RMHB

SOLCF

TCNNF

TGIFF

TLRY

UGRO

Cannabis Stock Movers For April 3, 2025

Guess? Expects Q1 Consolidated Net Revenue In US Dollars Increase Of 5.8% - 7.5%, Adj EPS Of $(0.74) - $(0.65), Est $(0.23)

WIIM

Guess? shares are trading higher after the company reported better-than-expected Q4 financial results.

Guess Inc Says There Is Opportunity For Greater China Market To Be Directly Developed & Managed By A Local, Highly Experienced Partner

Guess? Plans To Execute Business And Portfolio Optimization Expected To Unlock $30M In Operating Profit In FY27

Guess? Expects FY26 Revenue Increase Of 3.9% - 6.2% In US Dollars, Adjusted EPS Of $1.32 - $1.76, Est $2.02

ABBV

AbbVie Q1 2025 Earnings Include $248M IPR&D And Milestones Expense; For Q1 Sees Unfavorable Impact Of $0.13 To GAAP And Non-GAAP EPS; Q1 2025 Adjusted EPS Guidance $2.34-$2.38 Vs $2.51 Est.

Dividends

The Greenbrier Companies Announces Quarterly Cash Dividend Of $0.32 Per Share, Payable On May 13, 2025, To Stockholders Of Record As Of April 22, 2025. A 7% Increase From $0.30 Per Share

Press Releases

Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer's Transgenic Mice

Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs

Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo

Alzamend Neuro to Present at the Sequire Investor Summit

Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital

General

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

AIM ImmunoTech

Ainos

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Gr

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

Channel Therapeutics Corporation Common Stock

Channel Therapeutics

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

GT Biopharma

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals

Mainz Biomed

NuCana

Ocean Biomedical

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

Sunshine Biopharma

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Soligenix

XTL Biopharmaceuticals Ltd. - American Depositary Shares

XTL Biopharmaceuticals

Ascendiant Capital

Maxim Group

월요일 주요 미국 지수들은 상승세로 마감했다. 다우존스 산업평균지수는 0.6% 상승한 40,896.53에 마감했고, S&amp;P 500 지수는 거의 1% 상승한 5,608.25에 마감했다. 나스닥은 가장 큰 상승세를 보이며 17,876.77로 거의 1.4% 상승하며 하루를 마감했다.
이들은 하루 동안 소매 거래자와 투자자들의 주목을 받은 주요 종목들이다:
 엔비디아 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
엔비디아는 130달러에서 하루를 마감해 4.35% 상승했으며, 장중 최고가와 최저가는 각각 130달러, 123.42달러이다. 52주 신고가와 신저가는 각각 140.76달러와 39.23달러이다. 골드만삭스는 8월 28일로 예정된 이 회사 실적 발표를 앞두고 엔비디아에 대한 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40443620/goldman-sachs-is-bullish-on-nvidia-ahead-of-earnings-risk-reward-for-ai-stock-favor" target="_blank" rel="noopener" data-google-interstitial="false">낙관적인 입장을 재확인</a>하면서 클라우드 서비스 제공업체들과 기업들의 인공 지능에 대한 수요가 높다는 점을 언급했다.
 어드밴스드 마이크로 디바이시스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)
AMD는 4.52% 상승한 155.28달러에 마감했고, 장중 최고가와 최저가는 각각 155.37달러, 147.72달러이다. 52주 신고가와 신저가는 각각 227.3달러와 93.12달러이다. AMD는 49억 달러규모의 주식과 현금 거래로, 초대규모 컴퓨팅 회사들을 위한 인공 지능 인프라 공급자인 <a href="https://www.benzinga.com/m-a/24/08/40438854/amd-expands-ai-capabilities-acquires-zt-systems-in-major-4-9b-deal" target="_blank" rel="noopener" data-google-interstitial="false">ZT 시스템을 인수</a>하기로 결정한 후 주가가 상승했다.
알자멘드 뉴로 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALZN#NASDAQ">ALZN</a>)
알자멘드는 188.18% 상승한 5.85달러로 마감했으며, 장중 최고가는 15.06달러, 최저가는 5.72달러였다. 52주 최고가와 최저가는 45달러와 1.84달러이다. 이 회사는 PTSD로 고통받는 환자 치료를 위한 AL001의 최초 2상 임상 연구를 수행하기 위한 계약 연구 목적으로 매사추세츠 종합병원과 <a href="https://www.benzinga.com/24/08/40444701/crude-oil-down-2-alzamend-neuro-shares-spike-higher">파트너십</a>을 맺었다고 발표했다.
팔로알토 네트웍스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>)
팔로알토 네트웍스는 2.77% 상승한 343.36달러로 마감했으며, 장중 최고가와 최저가는 각각 344.48달러, 335.11달러이다. 52주 신고가와 신저가는 각각 380.84달러와 224.64달러이다. 이 회사는 <a href="https://www.benzinga.com/news/earnings/24/08/40449958/palo-alto-networks-q4-earnings-revenue-beat-eps-beat-strong-guidance-500m-added-to-buyback-and-more">4분기 이익</a>을 주당 1.51달러로 보고했는데, 이는 분석가의 예상인 1.41달러를 뛰어넘는 수치이다. 해당 분기 매출은 21억 8,900만 달러로 컨센서스 추정치 21억 6,200만 달러를 넘어섰다. 이 회사는 4분기 연속 이익 및 매출 추정치를 초과했다.
테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
테슬라는 3.12% 상승한 222.86달러로 장을 마감했으며, 장중 최고가는 222.98달러, 최저가는 214.09달러였다. 52주 최고가와 최저가는 278.97달러와 138.8달러이다. 테슬라의 일론 머스크 CEO는 러시아 지도자인 람잔 카디로프(Ramzan Kadyrov)에게 사이버트럭을 &#8216;기증&#8217;했다는 사실을 <a href="https://www.benzinga.com/news/24/08/40434114/elon-musk-denies-donating-tesla-cybertruck-to-ramzan-kadyrov-after-russian-general-showed-off-truck">부인</a>했다.
Photo by WHYFRAME on Shutterstock
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>가 제작했으며 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noopener noreferrer">Shivdeep Dhaliwal</a>가 편집했습니다.
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Alzamend Neuro

뉴스

에 대한 최신 뉴스 Alzamend Neuro (NASDAQ:ALZN) 주식

월요일, 8월 19, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌